{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04279847",
            "orgStudyIdInfo": {
                "id": "INCB 57643-103"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-506145-38-00",
                    "type": "REGISTRY",
                    "domain": "EU CT Number"
                }
            ],
            "organization": {
                "fullName": "Incyte Corporation",
                "class": "INDUSTRY"
            },
            "briefTitle": "Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms",
            "officialTitle": "A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms",
            "acronym": "LIMBER",
            "therapeuticArea": [
                "Rare Diseases",
                "Oncology and Hematology",
                "Other"
            ],
            "study": "safety-and-tolerability-study-of-in-participants-with-myelofibrosis-and-other-advanced-myeloid-neoplasms"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-02-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-02-18",
            "studyFirstSubmitQcDate": "2020-02-20",
            "studyFirstPostDateStruct": {
                "date": "2020-02-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Incyte Corporation",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms."
        },
        "conditionsModule": {
            "conditions": [
                "Myelofibrosis",
                "Myelodysplastic Syndrome",
                "Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome",
                "Myeloproliferative Neoplasm",
                "Relapsed or Refractory Primary Myelofibrosis",
                "Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)",
                "ET (Essential Thrombocythemia)"
            ],
            "keywords": [
                "Myelofibrosis",
                "myelodysplastic syndrome",
                "myelodysplastic/myeloproliferative neoplasm overlap syndrome",
                "myeloproliferative neoplasm",
                "BET protein inhibitor",
                "relapsed primary myelofibrosis",
                "refractory primary myelofibrosis",
                "secondary myelofibrosis",
                "post-polycythemia vera myelofibrosis",
                "post-essential thrombocythemia myelofibrosis",
                "LIMBER",
                "ET (essential thrombocythemia)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "monotherapy and ruxoltinib combination",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 216,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1 : INCB057643 Monotherapy",
                    "type": "EXPERIMENTAL",
                    "description": "INCB057643 dose escalation and dose expansion",
                    "interventionNames": [
                        "Drug: INCB057643"
                    ]
                },
                {
                    "label": "Part 2 : INCB057643 Combination with Ruxolitinib",
                    "type": "EXPERIMENTAL",
                    "description": "Combination arm in dose escalation and dose expansion",
                    "interventionNames": [
                        "Drug: INCB057643",
                        "Drug: Ruxolitinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "INCB057643",
                    "description": "INCB057643 dose escalation and dose expansion.",
                    "armGroupLabels": [
                        "Part 1 : INCB057643 Monotherapy",
                        "Part 2 : INCB057643 Combination with Ruxolitinib"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ruxolitinib",
                    "description": "Ruxolitinib will be administered twice a day using the dose described for each Cohort in the protocol for Part 2.",
                    "armGroupLabels": [
                        "Part 2 : INCB057643 Combination with Ruxolitinib"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of treatment-emergent adverse events",
                    "description": "Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with ruxolitinib.",
                    "timeFrame": "Up to approximately 9 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Spleen Volume Response",
                    "description": "Defined as achieving a protocol defined reduction at Week 24 relative to baseline as measured by MRI or CT scan.",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Duration of a Spleen Volume Response from baseline (MF only)",
                    "description": "Defined as the interval between the first spleen volume response and the date of the first measurement that no longer achieves the protocol defined criteria.",
                    "timeFrame": "Up to approximately 9 months"
                },
                {
                    "measure": "Symptom Response Rate (MF or ET)",
                    "description": "Defined as the proportion of participants who achieve a protocol defined reduction in Total Symptomatic Score (TSS) relative to baseline as measured by the MPN-symptom assessment form (SAF) TSS.",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Anemia Response (MF only)",
                    "description": "A hemoglobin increase of 1.5 g/dL relative to baseline for any \"rolling\" 12-week period during the study treatment period, if transfusion independent (TI) at baseline or Achieving TI for any \"rolling\" 12-week period during the study treatment period, if transfusion dependent (TD) at baseline.",
                    "timeFrame": "Up to approximately 9 months"
                },
                {
                    "measure": "Duration of Anemia Response (MF only)",
                    "description": "The interval from the first onset of anemia response to the earliest date of loss of anemia response that persists for at least 4 weeks or death from any cause for the TI participants at baseline or duration of RBC-TI period for participants achieving RBC-TI for at least 12 consecutive weeks during the study treatment period for the TD participants at baseline.",
                    "timeFrame": "Up to approximately 9 months"
                },
                {
                    "measure": "Changes in hemoglobin value from baseline (MF only)",
                    "description": "Defined as the mean change from baseline in the hemoglobin value over 12-week treatment periods.",
                    "timeFrame": "Up to approximately 9 months"
                },
                {
                    "measure": "Red Blood Cell (RBC) Transfusion Burden (MF only)",
                    "description": "Defined as the average number of RBC units per participant-month through Weeks 12, 24, and 48.",
                    "timeFrame": "Up to approximately 9 months"
                },
                {
                    "measure": "Overall response (ET only)",
                    "description": "Defined as proportion of participants with complete response or partial response and hematological improvement/response as per definition for ET.",
                    "timeFrame": "Up to approximately 9 months"
                },
                {
                    "measure": "Duration of platelet count reduction or White Blood Cell (WBC) count reduction (ET only)",
                    "description": "Defined as platelet count reduction or WBC count reduction lasting \u2265 12 weeks.",
                    "timeFrame": "Up to approximately 9 months"
                },
                {
                    "measure": "Bone Marrow (BM) Blast Complete Remission (MF, myelodysplastic syndrome (MDS), and MDS/myeloproliferative neoplasm (MPN))",
                    "description": "Defined as BM blasts achieving the protocol defined criteria.",
                    "timeFrame": "Up to approximately 9 months"
                },
                {
                    "measure": "BM Blast Partial Remission (MF, MDS, and MDS/MPN)",
                    "description": "Defined as BM blasts achieving the protocol defined criteria.",
                    "timeFrame": "Up to approximately 9 months"
                },
                {
                    "measure": "Peripheral Blast Complete Remission (MF, MDS, and MDS/MPN)",
                    "description": "Defined as peripheral blasts achieving the protocol defined criteria.",
                    "timeFrame": "Up to approximately 9 months"
                },
                {
                    "measure": "Peripheral Blast Partial Remission (MF, MDS, and MDS/MPN)",
                    "description": "Defined as peripheral blast achieving the protocol defined criteria.",
                    "timeFrame": "Up to approximately 9 months"
                },
                {
                    "measure": "Durable Blast Complete or Partial remission (MF, MDS, and MDS/MPN)",
                    "description": "Defined as achieving the protocol defined criteria.",
                    "timeFrame": "Up to approximately 9 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18 years and older at the time of signing the informed consent.\n* Part 1 Monotherapy: Participants with confirmed diagnosis of relapsed or refractory MF (primary, or post-PV and post-ET), MDS, MDS/MPN, or ET who have received at least 1 prior line of therapy; are either refractory, relapsed, or intolerant to the last therapy; and there is no available therapy that would provide clinical benefit in the opinion of the investigator.\n\n  * a. MF with measurable disease (palpable spleen and symptoms) as defined in the protocol and risk category of intermediate 2 or high according to DIPSS. MF participants must have received a JAK inhibitor(s), such as ruxolitinib.\n  * b. ET participants should have disease refractory to hydroxyurea as defined by the protocol.\n* Part 2 Combination with ruxolitinib.\n\n  * a. Primary MF or secondary MFs (post-PV MF and post-ET MF), histologically or cytologically confirmed, with measurable disease (palpable spleen and symptoms) as defined in the protocol, either currently receiving ruxolitinib with suboptimal response or JAKi-naive.\n  * b. Suboptimal response is defined as currently being treated with ruxolitinib monotherapy at a stable dose for \u2265 8 weeks immediately preceding the first dose of study treatment. One dose reduction due to toxicities within 8 weeks prior to Study Day 1 is permitted.\n  * c. JAKi-naive is defined as those participants that have no prior use of any JAK inhibitor, including ruxolitinib, and;\n  * d. Part 2 dose escalation: Risk category of intermediate-2 or high according to DIPSS.\n  * e. Part 2 dose expansion: Risk category of intermediate-1, intermediate-2, or high according to DIPSS.\n  * f. Part 2 dose expansion participants with chronic MF are defined as participants with bone marrow myeloblast percentage \\< 5% and no blasts detected/not persistent blast count in peripheral blood at screening or baseline, AND who are currently receiving ruxolitinib and having suboptimal response.\n  * g.Part 2 dose expansion participants with accelerated-phase MF are defined as having either a bone marrow myeloblast percentage \u2265 5% to \\< 20% or a myeloblast percentage \u2265 10% in peripheral blood on 2 occasions at least 2 weeks apart, AND are currently receiving ruxolitinib and have a suboptimal response.\n  * h.Part 2 dose expansion participants with JAKi-naive MF are eligible to receive ruxolitinib, with peripheral blood blast count of \\< 10% at the screening hematology assessment.\n* Must not be a candidate for potentially curative therapy, including hematopoietic stem cell transplantation.\n* ECOG performance status 0 to 2.\n* Life expectancy \u2265 24 weeks.\n* Willingness to avoid pregnancy or fathering children based on criteria.\n\n  * a. Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through 90 days after the last dose of study treatment and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed.\n  * b. Women of childbearing potential must have a negative serum pregnancy test at screening and before the first dose on Day 1 and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow-up. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed.\n  * c. Women of nonchildbearing potential (ie, surgically sterile with a hysterectomy and/or bilateral oophorectomy OR \u2265 12 months of amenorrhea without any other medical reasons such as treatment with anticancer agents) are eligible.\n\nExclusion Criteria:\n\n* Prior receipt of a BET inhibitor.\n* Receipt of anticancer medications or investigational drugs within the protocol-defined interval before the first dose of study treatment. For Part 2 JAKi-naive, prior use of a JAK inhibitor (including ruxolitinib) and no use of experimental drug therapy for MF or any other standard drug (except hydroxyurea) used for MF or another indication within 3 months of starting study drug. Hydroxyurea must be discontinued 3 weeks prior to starting study treatment. For participants with suboptimal response to ruxolitinib, ruxolitinib will continue at the participants' current ongoing doses, no ruxolitinib washout is needed.\n* Participants with exclusionary laboratory values at screening defined as, including, but not limited to,\n\n  * a. Platelets. Part 1 (monotherapy dose expansion, MF): \\< 75 \u00d7 109/L. Part 1 (monotherapy dose expansion, ET): \\< 450 \u00d7 109/L. Part 2 (combination dose escalation and expansion): \\< 75 \u00d7 109/L. Part 2 (combination dose expansion, JAKi-na\u00efve MF): \\< 100 \u00d7 109/L.\n  * b. Hemoglobin: Participants unwilling to receive red blood cell transfusion to treat low hemoglobin levels are excluded.\n  * c. ANC \\< 0.75 \u00d7 109/L.\n* inadequate renal, hepatic and coagulation functions as defined in the protocol.\n* Concurrent anticancer therapy other than the therapies being tested in this study.\n* Participants who have received allogeneic hematopoietic stem cell transplantation within 6 months of enrollment (unless approved by the medical monitor), or have active graft versus-host disease, or have received immunosuppressive therapy following allogeneic transplant within 2 weeks of the first dose of study treatment.\n* Unless approved by the medical monitor, may not have received autologous hematopoietic stem-cell transplant within 3 months before the first dose of study treatment.\n* Significant concurrent, uncontrolled medical condition, including but not limited to, significant GI disorder, history of or current clinically significant or uncontrolled cardiac disease, history or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful, and history of bleeding disorder or at a high risk of bleeding.\n* Active bacterial, fungal, parasitic, or viral infection that requires therapy.\n* Current use of prohibited medication as described in the protocol, including the use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half lives (whichever is longer) before the first dose of study treatment.\n\nOther protocol-defined Inclusion/Exclusion Criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Incyte Corporation Call Center (US)",
                    "role": "CONTACT",
                    "phone": "1.855.463.3463",
                    "email": "medinfo@incyte.com"
                },
                {
                    "name": "Incyte Corporation Call Center (ex-US)",
                    "role": "CONTACT",
                    "phone": "1.855.463.3463",
                    "email": "globalmedinfo@incyte.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of Alabama At Birmingham",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35294",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "University of Colorado Cancer Center",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "University of Miami Sylvester Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "Emory University-Winship Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "University of Iowa Hospital and Clinics",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Iowa City",
                    "state": "Iowa",
                    "zip": "52242",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.66113,
                        "lon": -91.53017
                    }
                },
                {
                    "facility": "Washington University School of Medicine",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Rutgers Cancer Institute of Nj",
                    "status": "COMPLETED",
                    "city": "New Brunswick",
                    "state": "New Jersey",
                    "zip": "08901",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.48622,
                        "lon": -74.45182
                    }
                },
                {
                    "facility": "Roswell Park Cancer Institute",
                    "status": "WITHDRAWN",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14263",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                },
                {
                    "facility": "Nyu Langone Health",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Mineola",
                    "state": "New York",
                    "zip": "11501",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.74927,
                        "lon": -73.64068
                    }
                },
                {
                    "facility": "Nyu Langone Laura and Isaac Perlmutter Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10016",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Weill Medical College of Cornell University",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10021",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University of North Carolina At Chapel Hill",
                    "status": "RECRUITING",
                    "city": "Chapel Hill",
                    "state": "North Carolina",
                    "zip": "27514",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.9132,
                        "lon": -79.05584
                    }
                },
                {
                    "facility": "University of Cincinnati Cancer Institute",
                    "status": "COMPLETED",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45267",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "Ohio State University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43210",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "Oregon Health and Science University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Baylor University Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75246",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Md Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Huntsman Cancer Institute At University of Utah",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "Seattle Cancer Care Alliance",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                },
                {
                    "facility": "Medical College of Wisconsin",
                    "status": "WITHDRAWN",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                },
                {
                    "facility": "Princess Margaret Cancer Center",
                    "status": "RECRUITING",
                    "city": "Toronto",
                    "state": "Ontario",
                    "zip": "M5G 2M9",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 43.70011,
                        "lon": -79.4163
                    }
                },
                {
                    "facility": "McGill University Jewish General Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Montreal",
                    "state": "Quebec",
                    "zip": "H3T 1E2",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "St Paul'S Hospital",
                    "status": "RECRUITING",
                    "city": "Vancouver",
                    "zip": "V6Z2A5",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 49.24966,
                        "lon": -123.11934
                    }
                },
                {
                    "facility": "Helsinki University Central Hospital",
                    "status": "RECRUITING",
                    "city": "Helsinki",
                    "zip": "00029",
                    "country": "Finland",
                    "geoPoint": {
                        "lat": 60.16952,
                        "lon": 24.93545
                    }
                },
                {
                    "facility": "Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola - Malpighi",
                    "status": "RECRUITING",
                    "city": "Bologna",
                    "zip": "40138",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 44.49381,
                        "lon": 11.33875
                    }
                },
                {
                    "facility": "Azienda Ospedaliero-Universitaria Careggi (Aouc)",
                    "status": "RECRUITING",
                    "city": "Firenze",
                    "zip": "50134",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 43.77925,
                        "lon": 11.24626
                    }
                },
                {
                    "facility": "Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Meldola",
                    "zip": "47014",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 44.12775,
                        "lon": 12.0626
                    }
                },
                {
                    "facility": "Fondazione Irccs Ca Granda Ospedale Maggiore",
                    "status": "RECRUITING",
                    "city": "Milan",
                    "zip": "20122",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.46427,
                        "lon": 9.18951
                    }
                },
                {
                    "facility": "Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Orbassano",
                    "zip": "10043",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.00547,
                        "lon": 7.53813
                    }
                },
                {
                    "facility": "Azienda Policlinico Umberto 1 Universita Sapienza Di Roma",
                    "status": "WITHDRAWN",
                    "city": "Rome",
                    "zip": "00161",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 41.89193,
                        "lon": 12.51133
                    }
                },
                {
                    "facility": "Azienda Ospedaliera Universitaria Integrata Di Verona - Centro Ricerche Cliniche Dr Verona",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Verona",
                    "zip": "371134",
                    "country": "Italy",
                    "geoPoint": {
                        "lat": 45.4299,
                        "lon": 10.98444
                    }
                },
                {
                    "facility": "Fujita Health University Hospital",
                    "status": "RECRUITING",
                    "city": "Aichi",
                    "zip": "470-1192",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 32.51879,
                        "lon": 130.62158
                    }
                },
                {
                    "facility": "Chiba University Hospital",
                    "status": "COMPLETED",
                    "city": "Chiba",
                    "zip": "260-8677",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.6,
                        "lon": 140.11667
                    }
                },
                {
                    "facility": "National Cancer Center Hospital East",
                    "status": "RECRUITING",
                    "city": "Chiba",
                    "zip": "277-8577",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.6,
                        "lon": 140.11667
                    }
                },
                {
                    "facility": "University of Yamanashi Hospital",
                    "status": "RECRUITING",
                    "city": "Chuo",
                    "zip": "409-3898",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.57779,
                        "lon": 139.71685
                    }
                },
                {
                    "facility": "Kyushu University Hospital",
                    "status": "COMPLETED",
                    "city": "Fukuoka",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 33.6,
                        "lon": 130.41667
                    }
                },
                {
                    "facility": "Kumamoto Shinto General Hospital",
                    "status": "RECRUITING",
                    "city": "Kumamoto",
                    "zip": "862-8655",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 32.80589,
                        "lon": 130.69182
                    }
                },
                {
                    "facility": "Radboud University Nijmegen Medical Center",
                    "status": "WITHDRAWN",
                    "city": "Nijmegen",
                    "zip": "6525 GA",
                    "country": "Netherlands",
                    "geoPoint": {
                        "lat": 51.8425,
                        "lon": 5.85278
                    }
                },
                {
                    "facility": "Germans Trias I Pujol",
                    "status": "RECRUITING",
                    "city": "Badalona",
                    "zip": "08916",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.45004,
                        "lon": 2.24741
                    }
                },
                {
                    "facility": "Hospital Universitario de Gran Canaria Dr. Negrin",
                    "status": "RECRUITING",
                    "city": "Las Palmas de Gran Canaria",
                    "zip": "35010",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 28.09973,
                        "lon": -15.41343
                    }
                },
                {
                    "facility": "Hospital Universitario 12 de Octubre",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28041",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario Virgen de La Arrixaca",
                    "status": "RECRUITING",
                    "city": "Murcia",
                    "zip": "30120",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 37.98704,
                        "lon": -1.13004
                    }
                },
                {
                    "facility": "Hospital Clinico Universitario de Salamanca",
                    "status": "RECRUITING",
                    "city": "Salamanca",
                    "zip": "37007",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.96882,
                        "lon": -5.66388
                    }
                },
                {
                    "facility": "Lincoln County Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "zip": "PE21 9QS",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 52.97633,
                        "lon": -0.02664
                    }
                },
                {
                    "facility": "United Lincolnshire Hospitals",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "zip": "PE21 9QS",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 52.97633,
                        "lon": -0.02664
                    }
                },
                {
                    "facility": "The Christie Nhs Foundation Trust Uk",
                    "status": "RECRUITING",
                    "city": "Manchester",
                    "zip": "M20 4BX",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 53.48095,
                        "lon": -2.23743
                    }
                },
                {
                    "facility": "University of Oxford",
                    "status": "RECRUITING",
                    "city": "Oxford",
                    "zip": "OX3 7LE",
                    "country": "United Kingdom",
                    "geoPoint": {
                        "lat": 51.75222,
                        "lon": -1.25596
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Related Info",
                    "url": "https://www.incyteclinicaltrials.com/limber/"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "Access to patient level data is not available for this study"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000011289",
                    "term": "Preleukemia"
                },
                {
                    "id": "D000011087",
                    "term": "Polycythemia Vera"
                },
                {
                    "id": "D000009190",
                    "term": "Myelodysplastic Syndromes"
                },
                {
                    "id": "D000055728",
                    "term": "Primary Myelofibrosis"
                },
                {
                    "id": "D000009196",
                    "term": "Myeloproliferative Disorders"
                },
                {
                    "id": "D000011086",
                    "term": "Polycythemia"
                },
                {
                    "id": "D000013922",
                    "term": "Thrombocytosis"
                },
                {
                    "id": "D000013920",
                    "term": "Thrombocythemia, Essential"
                },
                {
                    "id": "D000054437",
                    "term": "Myelodysplastic-Myeloproliferative Diseases"
                },
                {
                    "id": "D000013577",
                    "term": "Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004194",
                    "term": "Disease"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000001855",
                    "term": "Bone Marrow Diseases"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000011230",
                    "term": "Precancerous Conditions"
                },
                {
                    "id": "D000019046",
                    "term": "Bone Marrow Neoplasms"
                },
                {
                    "id": "D000019337",
                    "term": "Hematologic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000001791",
                    "term": "Blood Platelet Disorders"
                },
                {
                    "id": "D000001778",
                    "term": "Blood Coagulation Disorders"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "asFound": "Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M12149",
                    "name": "Myeloproliferative Disorders",
                    "asFound": "Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13972",
                    "name": "Polycythemia Vera",
                    "asFound": "Polycythemia Vera",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28312",
                    "name": "Primary Myelofibrosis",
                    "asFound": "Myelofibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13971",
                    "name": "Polycythemia",
                    "asFound": "Polycythemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16681",
                    "name": "Thrombocytosis",
                    "asFound": "Thrombocythemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16679",
                    "name": "Thrombocythemia, Essential",
                    "asFound": "Essential Thrombocythemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14164",
                    "name": "Preleukemia",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12145",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27707",
                    "name": "Myelodysplastic-Myeloproliferative Diseases",
                    "asFound": "Myelodysplastic/Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5134",
                    "name": "Bone Marrow Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14111",
                    "name": "Precancerous Conditions",
                    "relevance": "LOW"
                },
                {
                    "id": "M21070",
                    "name": "Bone Marrow Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M21314",
                    "name": "Hematologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5072",
                    "name": "Blood Platelet Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T1311",
                    "name": "Chronic Myeloproliferative Disorders",
                    "asFound": "Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3994",
                    "name": "Myelodysplastic/myeloproliferative Disease",
                    "asFound": "Myelodysplastic/Myeloproliferative Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4705",
                    "name": "Primary Myelofibrosis",
                    "asFound": "Myelofibrosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4614",
                    "name": "Polycythemia Vera",
                    "asFound": "Polycythemia Vera",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2144",
                    "name": "Essential Thrombocythemia",
                    "asFound": "Essential Thrombocythemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3993",
                    "name": "Myelodysplastic Syndromes",
                    "asFound": "Myelodysplastic Syndrome",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000712522",
                    "term": "INCB057643"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M341272",
                    "name": "INCB057643",
                    "asFound": "Hydroxymethylglutaryl-CoA Reductase Inhibitors",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}